EARLY BREAST CANCER

This study is testing a new treatment plan for early-stage HER2-positive breast cancer that aims to avoid chemotherapy for many patients. It uses a combination of targeted antibody drugs given as an injection under the skin. The treatment plan is adjusted after surgery based on w…

This study aimed to compare a new version of the cancer drug pertuzumab (called EG1206A) against the original version (Perjeta) in people with early-stage HER2-positive breast cancer. Participants would have received drug treatment before surgery, followed by surgery, then more d…

This study is testing if a new oral drug called giredestrant works better than the doctor's choice of standard hormone therapy to prevent cancer from coming back in people with early-stage, hormone-sensitive breast cancer. It involves over 4,000 participants who have already had …

This study is testing a new, potentially less toxic chemotherapy combination for people with early-stage HER2-positive breast cancer. Researchers want to see if this gentler treatment works as well as the standard, stronger chemotherapy at eliminating cancer before surgery. The s…

This study is testing if a combination of two hormone therapy drugs (letrozole and abemaciclib) works as well as or better than standard chemotherapy when given before surgery for certain types of early-stage breast cancer. It involves about 200 women whose cancer is hormone-sens…

This large, late-stage trial is testing whether adding a drug called ribociclib to standard hormone therapy can better prevent cancer from returning in people with a common type of early-stage breast cancer. It enrolled over 5,000 men and women who had surgery and are at higher r…

This study investigates whether young women with hormone-sensitive early breast cancer can safely pause their hormone-blocking therapy to try to become pregnant. It follows over 500 participants to see if this treatment break increases the risk of the cancer coming back. The rese…